Pharmicell Co (A005690) Q1 2026 earnings summary

Executive summary

• Operates two divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, electronic materials, flame retardants).

• Q1 FY2026 revenue was KRW 36.7 billion, with Bio-Chemical contributing 98% of sales.

• Major R&D focus on stem cell therapies for liver cirrhosis, erectile dysfunction, and chronic kidney disease, with multiple clinical trials ongoing.

• Maintains a robust patent portfolio and active government-supported research projects.

Financial highlights

• Q1 FY2026 revenue: KRW 36.7 billion, up from KRW 27.0 billion in Q1 FY2025.

• Operating income: KRW 13.1 billion; net income: KRW 11.7 billion for Q1 FY2026.

• Cash and equivalents at period end: KRW 22.9 billion.

• Total assets: KRW 168.1 billion; equity: KRW 132.8 billion.

• Dividend of KRW 50 per share for FY2025, up from KRW 20 per share in FY2024.

Segment performance

• Bio-Medical: Q1 FY2026 sales KRW 686 million (1.87% of total), mainly from cosmetics and cell therapy.

• Bio-Chemical: Q1 FY2026 sales KRW 36.0 billion (98.13% of total), led by nucleosides, PEG derivatives, and flame retardants.